Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15300843 | 0.86 | FPR3 (0.47) | DRD2CHRNB4CHRNA3ALDH1A1MCHR1 | |
| SCHEMBL15300841 | 0.86 | FPR3 (0.47) | DRD2CHRNB4CHRNA3ALDH1A1MCHR1 | |
| SCHEMBL23457760 | 0.85 | DRD2 (0.44) | DRD2ALDH1A1DRD4DRD3KMT2A | |
| SCHEMBL4534956 | 0.81 | CHRNB4 (0.53) | CHRNB4CHRNA3ALDH1A1MCHR1DRD4 | |
| SCHEMBL16468435 | 0.79 | LTA4H (0.49) | ALDH1A1DPP4 | |
| SCHEMBL3313710 | 0.78 | CHRNB4 (0.44) | CHRNB4CHRNA3ALDH1A1KMT2AMEN1 | |
| SCHEMBL3313944 | 0.78 | CHRNB4 (0.44) | CHRNB4CHRNA3ALDH1A1KMT2AMEN1 | |
| SCHEMBL4524496 | 0.78 | CHRNB4 (0.49) | CHRNB4CHRNA3ALDH1A1DRD4KMT2A | |
| SCHEMBL4287265 | 0.78 | KDM4E (0.45) | ALDH1A1KDM4ETDP1KMT2AMEN1 | |
| SCHEMBL14569577 | 0.76 | DPP4 (0.54) | CHRNB4CHRNA3ALDH1A1TDP1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | DRD2 4850/4885CHRNB4 4179/4885CHRNA3 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.